CD BioSciences recently launched a complete one-stop anti-aging drug development service package for pharmaceutical companies, research institutions and academic investigators developing cutting-edge anti-aging drugs. As a professional CRO in the aging research field, CD BioSciences combines technical platforms with industry experience to support partners throughout the entire anti-aging drug development cycle, from early discovery to preclinical stages.
The company's diversified anti-aging drug discovery services provide customized solutions across a wide range of targets and drug types. Target coverage includes key molecules and signaling pathways such as AMPK, mTOR, SIRT1, NF-κB, p53, and PI3K, which are closely associated with aging mechanisms. For drug types, the service encompasses mainstream anti-aging drug categories including senolytics, senomorphics, calorie restriction mimetics, autophagy inducers, anti-inflammatory drugs, antioxidants, telomerase activators, and mitochondrial modulators, meeting diversified client needs in target verification and lead compound screening.
CD BioSciences' anti-aging drug development services extend to a complete preclinical development system covering multiple key links to ensure scientific reliability. Its anti-aging pharmacology services include both in vitro and in vivo evaluations to verify therapeutic efficacy. The in vitro ADME services and in vivo pharmacokinetic services enable early assessment of pharmacokinetic behaviors, providing critical data for dose optimization, while in vitro toxicity testing, non-GLP toxicology, and safety pharmacology services comprehensively evaluate potential toxic effects on cardiovascular, respiratory, central nervous and other key physiological systems.
As a specialized aging disease model CRO, CD BioSciences has built a comprehensive and customizable preclinical aging model platform. Model customization services cover four major categories: organ-specific aging models including skin, cardiac, liver, lung, kidney, and muscle aging models; general aging models including cellular senescence models, yeast aging models, aging mouse/rat models, non-human primate aging models, and zebrafish aging models; longevity models including long-lived yeast strains, Drosophila, genetic mouse models, Fukomys mole-rat and naked mole-rat models; and aging-related disease models including neurodegenerative disease models, cardiovascular disease models, bone loss models, respiratory disease models, eye disease models, sarcopenia models, and progeria models.
These models can effectively assist clients in uncovering aging mechanisms, validating therapeutic targets, and evaluating the efficacy and safety of anti-aging drugs. The launch of these one-stop services addresses key challenges of lengthy timelines and high barriers to entry in anti-aging R&D. For more information about their research services, visit https://www.cd-biosciences.com.
The company's comprehensive approach could significantly impact the longevity pharmaceutical industry by streamlining development processes that traditionally require multiple specialized vendors. This consolidation of services may reduce time-to-market for anti-aging therapeutics while maintaining scientific rigor through integrated testing protocols. For business leaders and investors in the biotechnology sector, this development represents a potential acceleration point for anti-aging research pipelines that have shown promising scientific breakthroughs but face commercialization challenges.
CD BioSciences will continue to optimize its technical platforms and service systems, striving to become a top-selected partner for worldwide institutions in anti-aging drug development. The broader implications extend beyond pharmaceutical development to potential economic impacts as aging populations increase healthcare demands globally. Effective anti-aging interventions could transform healthcare economics and quality of life metrics across developed nations facing demographic shifts.
